αvβ3, αvβ5, and osteopontin are coordinately upregulated at early time points in a rabbit model of neointima formation

Journal of Cellular Biochemistry

Volumn 75, Issue 3, 1999, Pages 492-504

  Corjay, Martha H ^a   Diamond, Sheila M ^a   Schlingmann, Karen L ^a   Gibbs, Sandra K ^a   Stoltenborg, Janet K ^a   Racanelli, Adrienne L ^a  

^a DUPONT COMPANY   (United States)

Author keywords

c 3; c 5; Integrins; Neointima formation; Osteopontin; Restenosis models

Indexed keywords

ANTIBODY; INTEGRIN; MESSENGER RNA; OSTEOPONTIN; ALPHAVBETA5 INTEGRIN; LIGAND; SIALOGLYCOPROTEIN; SPP1 PROTEIN, HUMAN; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIVISION; CELL MIGRATION; CONTROLLED STUDY; FEMORAL ARTERY; INTIMA; MALE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; RESTENOSIS; SMOOTH MUSCLE FIBER; ANIMAL; ARTERIOSCLEROSIS; DISEASE MODEL; DRUG ANTAGONISM; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; METABOLISM; PATHOLOGY; RABBIT; RECURRENT DISEASE; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; UPREGULATION; VASCULAR SMOOTH MUSCLE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; ARTERIOSCLEROSIS; DISEASE MODELS, ANIMAL; FEMORAL ARTERY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTEGRINS; LIGANDS; MALE; MUSCLE, SMOOTH, VASCULAR; OSTEOPONTIN; RABBITS; RECEPTORS, VITRONECTIN; RECURRENCE; RNA, MESSENGER; SIALOGLYCOPROTEINS; TIME FACTORS; UP-REGULATION;

EID: 0033233458     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(19991201)75:3<492::AID-JCB13>3.0.CO;2-Z     Document Type: Article

References (40)

1. Basson CT, Kocher O, Basson MD, Asis A, Madri JA. 1992. Differential modulation of vascular cell integrin and extracellular matrix expression in vitro by TGF-β1 correlates with reciprocal effects on cell migration. J Cell Physiol 153:118-128.
2. Brown LF, Berse B, Van De Water L, Papadopoulos-Sergiou A, Perruzzi CA, Manseau EJ, Dvorak HF, Senger DR. 1992. Expression and distribution of osteopontin in human tissues: Widespread association with luminal epithelial surfaces. Mol Biol Cell 3:1169-1180.
3. Brown SL, Lundgren CH, Nordt T, Fujii S. 1994. Stimulation of migration of human aortic smooth muscle cells by vitronectin: implications for atherosclerosis, Cardiovasc Res 28:1815-1820.
4. Choi ET, Engel L, Callow AD, Sun S, Trachtenberg J, Santoro S, Ryan US. 1994. Inhibition of neointimal hyperplasia by blocking alpha V beta 3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg 19: 125-134.
5. Corjay MH, Diamond SM, Stoltenborg JK. 1996. αvβ3 integrin is not expressed uniformly throughout the vasculature: a survey of several species. Circulation 94:1517(abstract).
6. De Meyer GRY, Bult H, Van Hoydonck A, Jordaens FH, Buyssens N, Herman AG. 1991. Neointima formation impairs endothelial muscarinic receptors while enhancing prostacyclin mediated responses in the rabbit carotid artery. Circ Res 68:1669-1680.
7. De Meyer GRY, Van Put DJM, Kockx MM, Van Schil, Bosmans R, Bult H, Buyssens N, Vannmaele R, Herman AG. 1997. Possible mechanisms of collar-induced intimal thickening. Arterioscler Thromb Vasc Biol 17:1924-1930.
8. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. 1995. Definition of two angiogenic pathways by distinct αv integrals. Science 270:1500-1502.
9. Giachelli CM, Bae N, Almeida M, Denhardt D, Alpers CE, Schwartz SM. 1993. Osteopontin expression is elevated during neointimal formation in rat arteries and in human atherosclerotic plaques. J Clin Invest 92:1686-1696.
10. Giachelli CM, Liaw L, Murry CE, Schwartz SM, Almeida M. 1995. Osteopontin expression in cardiovascular diseases. Ann NY Acad Sci 760:109-126.
11. Graf K, Meehan WP, Chen JZ, Law RE, Fleck E, Hsueh WA. 1996. Upregulation of αv, β3 and β5-integrin mRNA during neointima formation in the rat aorta after balloon injury. Circulation 94:I-41(abstract).
12. Hirota S, Imakita M, Kohri K, Ito A, Morii E, Adachi S, Kim H, Kitamura Y, Yutani C, Nomura S. 1993. Expression of osteopontin messenger RNA by macrophages in atheroslcerotic plaques. Am J Pathol 143:1003-1008.
13. Hoshiga M, Alpers CE, Smith LL, Giachelli CM, Schwartz SM. 1995. αvβ3 integrin expression in normal and atherosclerotic artery. Circ Res 77:1129-1135.
14. Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. 1990. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 15:1667-1687.
15. Janat MF, Argraves WS, Liau G. 1992. Regulation of vascular smooth muscle cell integrin expression by transforming growth factor β1 and by platelet-derived growth factor-BB. J Cell Physiol 151:588-595.
16. Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW. 1992. Platelet-derived growth factor promotes smooth muscle migration and intimai thickening in a rat model of balloon angioplasty. J Clin Invest 89:507-511.
17. Jones JI, Prevette T, Gockerman A, Clemmons DR. 1996. Ligand occupancy of the αvβ3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor I. Proc Natl Acad Sci USA 93:2482-2487.
18. Kiefer MC, Bauer DM, Barr PJ. 1989. The cDNA and derived amino acid sequence for human osteopontin. Nucleic Acid Res 17:3306.
19. Kockx MM, De Meyer GRY, Jacob WA, Bult H, Herman AG. 1992. Triphasic sequence of neointimal formation in the cuffed carotid artery of the rabbit: Arterioslcer Thromb 12:1447-1457.
20. Kockx MM, De Meyer GRY, Andries LJ, Bult H, Jacob WA, Herman AG. 1993. The endothelium during cuff-induced neointima formation in the rabbit carotid artery. Arterioscler Thromb 13:1874-1884.
21. Le Breton H, Rabbani R, Plow EF, Mousa SA, Lincoff AM, Forudi F, Topol EJ. 1996. The role of integrins αIIbβ3 (glycoprotein IIb/IIIa) and αvβ3 (the vitronectin receptor) in a guinea pig model of restenosis. Circulation 94:I-517(abstract).
22. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM. 1995a. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins: role of αvβS in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 95:713-724.
23. Liaw L, Lindner V, Schwartz SM, Chambers AF, Giachelli CM. 1995b. Osteopontin and β3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. Circ Res 77:665-672.
24. Liaw L, Lombardi DM, Almeida MM, Schwartz SM, deBlois D, Giachelli CM. 1997. Neutralizing antibodies directed against osteopontin inhibit rat carotid neointimal thickening after endothelial denudation. Arterioscler Thromb Vasc Biol 17:188-193.
25. Lincoff AM, Tcheng JE, Ellis SG, Moliterno DJ, Kitt MM, Debowey D, Topol EJ. 1995. Randomized trial of platelet glycoprotein IIb/IIIa inhibition with integrelin for prevention of restenosis following coronary intervention. The IMPACT-Angiographic substudy. Circulation 92: I607(abstract).
26. Lindner V, Majack RA, Reidy MA. 1990. Basic fibroblast growth factor stimulates endothelial regrowth and proliferation in denuded arteries. J Clin Invest 85:2004-2008.
27. Liu MW, Roubin GS, King SB III. 1989. Restenosis after coronary angioplasty: potential biological determinants and role of intimal hyperplasia. Circulation 79:1374-1387.
28. Lopez CA, Hoyer JR, Wilson PD, Waterhouse P, Denhardt DT. 1993. Heterogeneity of osteopontin expresssion among nephrons in mouse kidneys and enhanced expression in sclerotic glomeruli. Lab Invest 69:355-363.
29. Matsuno H, Stassen JM, Vermylen J, Deckmyn H. 1994. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation 90:2203-2206.
30. Nobuyoshi M, Kimura T, Nosaka H, Mioka S, Ueno K, Yokoi H, Hamsaki N, Horiuchi H, Ohishi H. 1988. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol 12:616-623.
31. O'Brien ER, Garvin MR, Stewart DK, Hinohara T, Simpson JB, Schwartz SM, Giachelli CM. 1994. Osteopontin is synthesized by macrophage, smooth muscle and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb 14:1648-1656.
32. Rabb H, Barroso-Vicens E, Adams R, Pow-Sang J, Ramirez G. 1996. AlphaV/Beta3 and AlphaV/Beta5 integrin distribution in neoplastic kidney. Amer J Nephrol 16:402-408.
33. Serruys PW, Luiten HE, Beatt KJ, Geuskens R, De Feyter PJ, Van den Brand M, Reiber JHC, Ten Katen HJ, van Es GA, Hugenholtz PG. 1988. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1,2,3, and 4 months. Circulation 77:361-371.
34. Shanahan CS, Weissberg PL, Metcalfe JC. 1993. Isolation of gene markers of differentiated and proliferating vascular smooth muscle cells. Circ Res 73:193-204.
35. Smith JW, Vestal DJ, Irwin SV, Burke TA, Cheresh DA. 1990. Purification and functional characterization of integrin αvβ5: An adhesion receptor for vitronectin. J Biol Chem 265:11008-11013.
36. Srivatsa SS, Fitzpatrick LA, Tsao PW, Reilly TM, Holmes DR Jr, Schwartz RS, Mousa SA. 1997. Selective αvβ3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: Evidence for the functional importance of integrin αvβ3 and osteopontin expression during neointima formation. Cardiovasc Res 36:408-428.
37. Tezuka K, Sato T, Kamioka H, Nijweide PJ, Tanaka K, Matsuo T, Ohta M, Kurihara N, Hakeda Y, Kumegawa M. 1992. Identification of osteopontin in isolated rabbit osteoclasts. Biochem Biophys Res Commun 186:911-917.
38. Topol EJ, Califf RM, Weisman HF, et al. on behalf of the EPIC investigators. 1994. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 343:881-886.
39. Walton H, Corjay MH, Diamond SM, Kearney M, Strzemienski P, Solomon K, Mousa SA, Reilly TR. 1996. Evaluation of monoclonal antibodies against the integrin receptor αvβ3. FASEB 10:A692(abstract).
40. Wilcox JN. 1993. Fundamental principles of in situ hybridization. J Histochem Cytochem 41:1725-1733.